Medicus Pharma shares updates on basal cell carcinoma trials
Esme Needham | December 2, 2025 | News story | Research and Development |Â Â Medicus Pharma, OncologyÂ
Medicus Pharma has announced updates on the progress of SKNJCT-003 and SKNJCT-004, its clinical trials studying the efficacy of a non-invasive treatment for basal cell carcinoma (BCC).
BCC is the most common cancer in the US, with more than five million cases reported each year. It develops on areas of skin exposed to the sun, presenting as skin lesions or ulceration. While BCC is highly treatable if found early, an innovative non-invasive treatment would be highly impactful for both patients and healthcare systems.
The ongoing trials are run by SkinJect, a subsidiary of Medicus. The treatment they are designed to evaluate is administered via dissolvable doxorubicin-containing microneedle arrays (D-MNA). Findings from an interim analysis of SKNJCT-003, announced in March 2025, demonstrated more than 60% clinical clearance, though these results are preliminary.
The company recently received a positive opinion from the US Food and Drug Administration (FDA) on the development of the SkinJect treatment, allowing it to follow the FDA’s regulatory pathway to approval and marketing. Additionally, in November 2025, the company received full regulatory and ethical approvals in the UK to expand the SKNJCT-003 trial.
In October 2025, the first patient was treated in the SKNJCT-004 study, which is currently underway in the United Arab Emirates (UAE). The study is expected to randomise 36 patients across six UAE sites.
Other recent announcements from Medicus include the acquisition of late clinical-stage biotechnology company Antev, which is developing the next-generation prostate cancer therapy Teverelix, and a strategic collaboration with the Gorlin Syndrome Alliance.
Medicus is a biotechnology and life sciences company focused on the discovery and development of innovative therapies. SkinJect, a development-stage life sciences company, is a wholly-owned subsidiary of Medicus.
